Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.


Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
08 2022
Historique:
received: 10 11 2021
accepted: 01 07 2022
pubmed: 12 8 2022
medline: 23 8 2022
entrez: 11 8 2022
Statut: ppublish

Résumé

Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)

Identifiants

pubmed: 35953718
doi: 10.1038/s41591-022-01927-8
pii: 10.1038/s41591-022-01927-8
pmc: PMC9388377
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1662-1671

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Cairns, J. Mutation selection and the natural history of cancer. Nature 255, 197–200 (1975).
pubmed: 1143315 doi: 10.1038/255197a0
Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976).
pubmed: 959840 doi: 10.1126/science.959840
Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184, 2239–2254 (2021).
pubmed: 33831375 pmcid: 8054914 doi: 10.1016/j.cell.2021.03.009
Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
pubmed: 32025013 pmcid: 7054212 doi: 10.1038/s41586-019-1907-7
Ferrando, A. A. & López-Otín, C. Clonal evolution in leukemia. Nat. Med. 23, 1135–1145 (2017).
pubmed: 28985206 doi: 10.1038/nm.4410
Ding, W. Richter transformation in the era of novel agents. Hematology 2018, 256–263 (2018).
pubmed: 30504319 pmcid: 6245983 doi: 10.1182/asheducation-2018.1.256
Maddocks, K. J. et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 1, 80 (2015).
pubmed: 26182309 pmcid: 4520535 doi: 10.1001/jamaoncol.2014.218
Ahn, I. E. et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129, 1469–1479 (2017).
pubmed: 28049639 pmcid: 5356450 doi: 10.1182/blood-2016-06-719294
Jain, P. et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125, 2062–2067 (2015).
pubmed: 25573991 pmcid: 4467871 doi: 10.1182/blood-2014-09-603670
Landau, D. A. et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat. Commun. 8, 2185 (2017).
pubmed: 29259203 pmcid: 5736707 doi: 10.1038/s41467-017-02329-y
Beà, S. et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter’s syndrome). Am. J. Pathol. 161, 957–968 (2002).
pubmed: 12213724 pmcid: 1867253 doi: 10.1016/S0002-9440(10)64256-3
Scandurra, M. et al. Genomic profiling of Richter’s syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematol. Oncol. 28, 62–67 (2010).
pubmed: 20014148 doi: 10.1002/hon.932
Rossi, D. et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117, 3391–3401 (2011).
pubmed: 21266718 doi: 10.1182/blood-2010-09-302174
Fabbri, G. et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J. Exp. Med. 210, 2273–2288 (2013).
pubmed: 24127483 pmcid: 3804949 doi: 10.1084/jem.20131448
Chigrinova, E. et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122, 2673–2682 (2013).
pubmed: 24004666 doi: 10.1182/blood-2013-03-489518
Klintman, J. et al. Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. Blood 137, 2800–2816 (2021).
pubmed: 33206936 pmcid: 8163497 doi: 10.1182/blood.2020005650
Chakraborty, S. et al. B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation. Blood 138, 1053–1066 (2021).
pubmed: 33900379 doi: 10.1182/blood.2020008276
Anderson, M. A. et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 129, 3362–3370 (2017).
pubmed: 28473407 doi: 10.1182/blood-2017-01-763003
Miller, C. R. et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 1, 1584–1588 (2017).
pubmed: 29296799 pmcid: 5728464 doi: 10.1182/bloodadvances.2017007302
Kadri, S. et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 1, 715–727 (2017).
pubmed: 29296715 pmcid: 5728051 doi: 10.1182/bloodadvances.2016003632
Herling, C. D. et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat. Commun. 9, 727 (2018).
pubmed: 29463802 pmcid: 5820258 doi: 10.1038/s41467-018-03170-7
Villamor, N. et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 27, 1100–1106 (2013).
pubmed: 23295735 doi: 10.1038/leu.2012.357
De Paoli, L. et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk. Lymphoma 54, 1087–1090 (2013).
pubmed: 23039309 doi: 10.3109/10428194.2012.723706
Rossi, D. et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br. J. Haematol. 158, 426–429 (2012).
pubmed: 22571487 doi: 10.1111/j.1365-2141.2012.09155.x
Chitalia, A. et al. Descriptive analysis of genetic aberrations and cell of origin in Richter transformation. Leuk. Lymphoma 60, 971–979 (2019).
pubmed: 30632835 doi: 10.1080/10428194.2018.1516878
Benatti, S. et al. IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. Hematol. Oncol. 39, 707–711 (2021).
pubmed: 34431535 doi: 10.1002/hon.2915
Minici, C. et al. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat. Commun. 8, 15746 (2017).
pubmed: 28598442 pmcid: 5472768 doi: 10.1038/ncomms15746
Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519–524 (2015).
pubmed: 26200345 doi: 10.1038/nature14666
Kasar, S. et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866 (2015).
pubmed: 26638776 doi: 10.1038/ncomms9866
Maura, F. et al. A practical guide for mutational signature analysis in hematological malignancies. Nat. Commun. 10, 2969 (2019).
pubmed: 31278357 pmcid: 6611883 doi: 10.1038/s41467-019-11037-8
Arthur, S. E. et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat. Commun. 9, 4001 (2018).
pubmed: 30275490 pmcid: 6167379 doi: 10.1038/s41467-018-06354-3
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018 pmcid: 7054213 doi: 10.1038/s41586-020-1943-3
Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836 (2019).
pubmed: 30982602 pmcid: 6506336 doi: 10.1016/j.cell.2019.03.001
Rustad, E. H. et al. Timing the initiation of multiple myeloma. Nat. Commun. 11, 1917 (2020).
pubmed: 32317634 pmcid: 7174344 doi: 10.1038/s41467-020-15740-9
de Kanter, J. K. et al. Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients. Cell Stem Cell 28, 1726–1739 (2021).
pubmed: 34496298 pmcid: 8516432 doi: 10.1016/j.stem.2021.07.012
Pich, O. et al. The mutational footprints of cancer therapies. Nat. Genet. 51, 1732–1740 (2019).
pubmed: 31740835 pmcid: 6887544 doi: 10.1038/s41588-019-0525-5
Gaiti, F. et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature 569, 576–580 (2019).
pubmed: 31092926 pmcid: 6533116 doi: 10.1038/s41586-019-1198-z
Gemenetzi, K. et al. Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169. Blood 137, 1895–1904 (2021).
pubmed: 33036024 doi: 10.1182/blood.2020005216
Bagnara, D. et al. Post-transformation IGHV-IGHD-IGHJ mutations in chronic lymphocytic leukemia B cells: implications for mutational mechanisms and impact on clinical course. Front. Oncol. 11, 1769 (2021).
doi: 10.3389/fonc.2021.640731
Calissano, C. et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 114, 4832–4842 (2009).
pubmed: 19789386 pmcid: 2925477 doi: 10.1182/blood-2009-05-219634
Calissano, C. et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol. Med. 17, 1374–1382 (2011).
pubmed: 21968788 pmcid: 3321822 doi: 10.2119/molmed.2011.00360
Cui, B. et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 124, 546–554 (2014).
pubmed: 24914134 pmcid: 4110661 doi: 10.1182/blood-2014-03-559690
Penter, L. et al. Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history. Cancer Discov. 11, 3048–3063 (2021).
pubmed: 34112698 pmcid: 8660953 doi: 10.1158/2159-8290.CD-21-0276
Beekman, R. et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat. Med. 24, 868–880 (2018).
pubmed: 29785028 pmcid: 6363101 doi: 10.1038/s41591-018-0028-4
Chen, C.-L. et al. Arginine is an epigenetic regulator targeting TEAD4 to modulate OXPHOS in prostate cancer cells. Nat. Commun. 12, 2398 (2021).
pubmed: 33893278 pmcid: 8065123 doi: 10.1038/s41467-021-22652-9
Rajbhandari, P. et al. Cross-cohort analysis identifies a TEAD4–MYCN positive feedback loop as the core regulatory element of high-risk neuroblastoma. Cancer Discov. 8, 582–599 (2018).
pubmed: 29510988 pmcid: 5967627 doi: 10.1158/2159-8290.CD-16-0861
Maffei, R. et al. IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. Leukemia 35, 1330–1343 (2021).
pubmed: 33623139 doi: 10.1038/s41375-021-01178-5
Patterson, D. G. et al. An IRF4–MYC–mTORC1 integrated pathway controls cell growth and the proliferative capacity of activated B cells during B cell differentiation in vivo. J. Immunol. 207, 1798–1811 (2021).
pubmed: 34470852 doi: 10.4049/jimmunol.2100440
Duran-Ferrer, M. et al. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. Nat. Cancer 1, 1066–1081 (2020).
pubmed: 34079956 pmcid: 8168619 doi: 10.1038/s43018-020-00131-2
Hasan, M. K., Ghia, E. M., Rassenti, L. Z., Widhopf, G. F. & Kipps, T. J. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. Leukemia 35, 1621–1630 (2021).
pubmed: 33097837 doi: 10.1038/s41375-020-01055-7
Ntoufa, S., Vilia, M. G., Stamatopoulos, K., Ghia, P. & Muzio, M. Toll-like receptors signaling: a complex network for NF-κB activation in B-cell lymphoid malignancies. Semin. Cancer Biol. 39, 15–25 (2016).
pubmed: 27402288 doi: 10.1016/j.semcancer.2016.07.001
Monti, S. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105, 1851–1861 (2005).
pubmed: 15550490 doi: 10.1182/blood-2004-07-2947
Caro, P. et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22, 547–560 (2012).
pubmed: 23079663 pmcid: 3479446 doi: 10.1016/j.ccr.2012.08.014
Norberg, E. et al. Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death Differ. 24, 251–262 (2017).
pubmed: 27768122 doi: 10.1038/cdd.2016.116
Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036–1046 (2018).
pubmed: 29892070 doi: 10.1038/s41591-018-0052-4
Vangapandu, H. V. et al. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget 9, 24980–24991 (2018).
pubmed: 29861847 pmcid: 5982765 doi: 10.18632/oncotarget.25166
Zhang, L. et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci. Transl. Med. 11, eaau1167 (2019).
pubmed: 31068440 doi: 10.1126/scitranslmed.aau1167
Varano, G. et al. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. Nature 546, 302–306 (2017).
pubmed: 28562582 doi: 10.1038/nature22353
Dadashian, E. L. et al. TLR signaling is activated in lymph node–resident CLL cells and is only partially inhibited by ibrutinib. Cancer Res. 79, 360–371 (2019).
pubmed: 30498085 doi: 10.1158/0008-5472.CAN-18-0781
Chan, K.-L. et al. Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors. Br. J. Haematol. 177, 324–328 (2017).
pubmed: 27196127 doi: 10.1111/bjh.14062
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 pmcid: 2705234 doi: 10.1093/bioinformatics/btp324
Nadeu, F. et al. IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. Nat. Commun. 11, 3390 (2020).
pubmed: 32636395 pmcid: 7341758 doi: 10.1038/s41467-020-17095-7
Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
pubmed: 21221095 pmcid: 3346182 doi: 10.1038/nbt.1754
Jones, D. et al. cgpCaVEManWrapper: simple execution of CaVEMan in order to detect somatic single nucleotide variants in NGS data. Curr. Protoc. Bioinforma. 56, 15.10.1–15.10.18 (2016).
doi: 10.1002/cpbi.20
McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508 doi: 10.1101/gr.107524.110
Fan, Y. et al. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biol. 17, 178 (2016).
pubmed: 27557938 pmcid: 4995747 doi: 10.1186/s13059-016-1029-6
Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience https://doi.org/10.1093/gigascience/giab008 (2021).
Moncunill, V. et al. Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Nat. Biotechnol. 32, 1106–1112 (2014).
pubmed: 25344728 doi: 10.1038/nbt.3027
Raine, K. M. et al. cgpPindel: identifying somatically acquired insertion and deletion events from paired end sequencing. Curr. Protoc. Bioinforma. 52, 15.7.1–12 (2015).
doi: 10.1002/0471250953.bi1507s52
Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581–591 (2018).
pubmed: 29535149 pmcid: 5880247 doi: 10.1101/gr.221028.117
Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912–918 (2014).
pubmed: 25017105 pmcid: 4753679 doi: 10.1038/ng.3036
Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. (Austin). 6, 80–92 (2012).
pubmed: 22728672 pmcid: 3679285 doi: 10.4161/fly.19695
Nadeu, F. et al. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia 32, 645–653 (2018).
pubmed: 28924241 doi: 10.1038/leu.2017.291
Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
pubmed: 22300766 pmcid: 3290792 doi: 10.1101/gr.129684.111
Lai, Z. et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 44, e108 (2016).
pubmed: 27060149 pmcid: 4914105 doi: 10.1093/nar/gkw227
Wilm, A. et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 40, 11189–11201 (2012).
pubmed: 23066108 pmcid: 3526318 doi: 10.1093/nar/gks918
Muller, E. et al. OutLyzer: software for extracting low-allele-frequency tumor mutations from sequencing background noise in clinical practice. Oncotarget 7, 79485–79493 (2016).
pubmed: 27825131 pmcid: 5346729 doi: 10.18632/oncotarget.13103
Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).
pubmed: 22608083 pmcid: 3428864 doi: 10.1016/j.cell.2012.04.023
Raine, K. M. et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr. Protoc. Bioinforma. 56, 15.9.1–15.9.17 (2016).
doi: 10.1002/cpbi.17
Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).
pubmed: 27100738 pmcid: 4839673 doi: 10.1371/journal.pcbi.1004873
Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).
pubmed: 27135926 pmcid: 4910866 doi: 10.1038/nature17676
Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333–i339 (2012).
pubmed: 22962449 pmcid: 3436805 doi: 10.1093/bioinformatics/bts378
Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011).
pubmed: 21215367 pmcid: 3065307 doi: 10.1016/j.cell.2010.11.055
Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226–1236 (2013).
pubmed: 23498933 doi: 10.1016/j.cell.2013.02.023
Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013).
pubmed: 23622249 pmcid: 3690918 doi: 10.1016/j.cell.2013.03.021
Shen, M. M. Chromoplexy: a new category of complex rearrangements in the cancer genome. Cancer Cell 23, 567–569 (2013).
pubmed: 23680143 pmcid: 3673705 doi: 10.1016/j.ccr.2013.04.025
Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112–121 (2020).
pubmed: 32025012 pmcid: 7025897 doi: 10.1038/s41586-019-1913-9
Maura, F. et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 10, 3835 (2019).
pubmed: 31444325 pmcid: 6707220 doi: 10.1038/s41467-019-11680-1
Dentro, S. C., Wedge, D. C. & Van Loo, P. Principles of reconstructing the subclonal architecture of cancers. Cold Spring Harb. Perspect. Med. 7, a026625 (2017).
pubmed: 28270531 pmcid: 5538405 doi: 10.1101/cshperspect.a026625
Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600–606 (2016).
pubmed: 27111033 pmcid: 4936490 doi: 10.1038/ng.3557
Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574, 532–537 (2019).
pubmed: 31645730 doi: 10.1038/s41586-019-1672-7
Yang, F. et al. Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nat. Cancer 2, 819–834 (2021).
pubmed: 35122027 doi: 10.1038/s43018-021-00230-8
Koren, A. et al. Differential relationship of DNA replication timing to different forms of human mutation and variation. Am. J. Hum. Genet. 91, 1033–1040 (2012).
pubmed: 23176822 pmcid: 3516607 doi: 10.1016/j.ajhg.2012.10.018
Haradhvala, N. J. et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164, 538–549 (2016).
pubmed: 26806129 pmcid: 4753048 doi: 10.1016/j.cell.2015.12.050
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
pubmed: 24695404 pmcid: 4103590 doi: 10.1093/bioinformatics/btu170
Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363–1369 (2014).
pubmed: 24478339 pmcid: 4016708 doi: 10.1093/bioinformatics/btu049
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Kopylova, E., Noé, L. & Touzet, H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics 28, 3211–3217 (2012).
pubmed: 23071270 doi: 10.1093/bioinformatics/bts611
Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525–527 (2016).
pubmed: 27043002 doi: 10.1038/nbt.3519
Kuipers, J., Jahn, K., Raphael, B. J. & Beerenwinkel, N. Single-cell sequencing data reveal widespread recurrence and loss of mutational hits in the life histories of tumors. Genome Res. 27, 1885–1894 (2017).
pubmed: 29030470 pmcid: 5668945 doi: 10.1101/gr.220707.117
Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).
pubmed: 33087716 pmcid: 7577981 doi: 10.1038/s41467-020-19119-8
Picelli, S. et al. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat. Methods 10, 1096–1098 (2013).
pubmed: 24056875 doi: 10.1038/nmeth.2639
Stoeckius, M. et al. Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biol. 19, 224 (2018).
pubmed: 30567574 pmcid: 6300015 doi: 10.1186/s13059-018-1603-1
Parekh, S., Ziegenhain, C., Vieth, B., Enard, W. & Hellmann, I. zUMIs - A fast and flexible pipeline to process RNA sequencing data with UMIs. Gigascience https://doi.org/10.1093/gigascience/giy059 (2018).
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281–291 (2019).
pubmed: 30954476 pmcid: 6625319 doi: 10.1016/j.cels.2018.11.005
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819 pmcid: 6884693 doi: 10.1038/s41592-019-0619-0
Gnaiger, E., Steinlechner-Maran, R., Méndez, G., Eberl, T. & Margreiter, R. Control of mitochondrial and cellular respiration by oxygen. J. Bioenerg. Biomembr. 27, 583–596 (1995).
pubmed: 8746845 doi: 10.1007/BF02111656
Mongini, P. K. A. et al. TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells. J. Immunol. 195, 901–923 (2015).
pubmed: 26136429 pmcid: 4505957 doi: 10.4049/jimmunol.1403189

Auteurs

Ferran Nadeu (F)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. nadeu@recerca.clinic.cat.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. nadeu@recerca.clinic.cat.

Romina Royo (R)

Barcelona Supercomputing Center (BSC), Barcelona, Spain.

Ramon Massoni-Badosa (R)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

Heribert Playa-Albinyana (H)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Beatriz Garcia-Torre (B)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Martí Duran-Ferrer (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Kevin J Dawson (KJ)

Wellcome Sanger Institute, Hinxton, UK.

Marta Kulis (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Ander Diaz-Navarro (A)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.

Neus Villamor (N)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.

Vicente Chapaprieta (V)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Ana Dueso-Barroso (A)

Barcelona Supercomputing Center (BSC), Barcelona, Spain.

Julio Delgado (J)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.
Universitat de Barcelona, Barcelona, Spain.

Riccardo Moia (R)

Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

Sara Ruiz-Gil (S)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

Domenica Marchese (D)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

Ariadna Giró (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Núria Verdaguer-Dot (N)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Mónica Romo (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Guillem Clot (G)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Maria Rozman (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.

Gerard Frigola (G)

Hospital Clínic of Barcelona, Barcelona, Spain.

Alfredo Rivas-Delgado (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.

Tycho Baumann (T)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.
Hospital Universitario 12 de Octubre, Madrid, Spain.

Miguel Alcoceba (M)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Biología Molecular e Histocompatibilidad, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain.

Marcos González (M)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Biología Molecular e Histocompatibilidad, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain.

Fina Climent (F)

Hospital Universitari de Bellvitge-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Pau Abrisqueta (P)

Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

Josep Castellví (J)

Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

Francesc Bosch (F)

Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

Marta Aymerich (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.

Anna Enjuanes (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Sílvia Ruiz-Gaspà (S)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Armando López-Guillermo (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.
Universitat de Barcelona, Barcelona, Spain.

Pedro Jares (P)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.
Universitat de Barcelona, Barcelona, Spain.

Sílvia Beà (S)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.
Universitat de Barcelona, Barcelona, Spain.

Salvador Capella-Gutierrez (S)

Barcelona Supercomputing Center (BSC), Barcelona, Spain.

Josep Ll Gelpí (JL)

Barcelona Supercomputing Center (BSC), Barcelona, Spain.
Universitat de Barcelona, Barcelona, Spain.

Núria López-Bigas (N)

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

David Torrents (D)

Barcelona Supercomputing Center (BSC), Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

Peter J Campbell (PJ)

Wellcome Sanger Institute, Hinxton, UK.

Ivo Gut (I)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Davide Rossi (D)

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Gianluca Gaidano (G)

Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

Xose S Puente (XS)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain.

Pablo M Garcia-Roves (PM)

Universitat de Barcelona, Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Dolors Colomer (D)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hospital Clínic of Barcelona, Barcelona, Spain.
Universitat de Barcelona, Barcelona, Spain.

Holger Heyn (H)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Francesco Maura (F)

Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.

José I Martín-Subero (JI)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Universitat de Barcelona, Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

Elías Campo (E)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ecampo@clinic.cat.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. ecampo@clinic.cat.
Hospital Clínic of Barcelona, Barcelona, Spain. ecampo@clinic.cat.
Universitat de Barcelona, Barcelona, Spain. ecampo@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH